Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

AML
Bladder Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Genomic Testing
GI Cancers
GIST
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Liquid Biopsies
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Thyroid Cancers
More >>

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

Targeted Therapies in Oncology
July 2

Clinical Articles

More Actionable Targets Improve Therapy in NSCLC
Updated KEYNOTE-048 Data Show PD-1 Inhibitor Improves OS in HNSCC
Barriers to Interpreting Results in Molecular Profiling Exist Among Oncologists
KEYNOTE-048 Leads to First-Line Advances in Monotherapy, Chemotherapy for Head and Neck Cancer
IDH Mutations Offer Hope as a Prognostic Indicator and Treatable Target in Gliomas
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.